“I’d at least like to see them go through peer review before hanging my hat on them,” said Joshua Skydel.
As the U.S. Food and Drug Administration moves to revoke its approval of the rare disease drug Tavneos, legal, regulatory, and institutional hurdles reveal that pulling a medication from the market is a complex, contested bureaucratic process, as Undark reported. Under the law, Tavneos “really shouldn’t remain on the market,” according to Skydel, a clinical fellow in rheumatology at Yale New Haven Hospital and a researcher at the Yale Collaboration for Regulatory Rigor, Integrity, and Transparency.
Evidentiary Burdens and Unpublished Trials
The regulatory conflict centers on strict statutory standards for drug approval, which demand substantial evidence of safety and effectiveness. Skydel pointed out that the pivotal trial backing Tavneos has been called into question, with several supporting studies cited by manufacturer Amgen still unpublished.
The FDA's move to pull Tavneos due to manipulated drug trial data is a concerning regulatory development in the realm of vasculitis treatment. The drug's approval in 2022 and subsequent acquisition by Amgen now face scrutiny over unblinded data manipulation, raising serious… pic.twitter.com/A1tiLJ1haC
Real-World Data and International Rejections
Meanwhile, additional clinical evidence gathered since the initial approval is unlikely to shift the regulatory calculus. “I suspect real world data, much of which were already available when we requested withdrawal in April, will not meet the FDA’s evidentiary bar for approval,” wrote Høeg. The assessment noted that the data proved insufficient for ongoing marketing authorization in both the European Union and the United Kingdom.
Post-Marketing Deadlines and Oversight
Compounding the scrutiny, Amgen fell behind on deadlines for post-marketing studies requested by the FDA at the time of the drug’s approval. “This episode really, for me, highlighted the way that drugs are allowed to reach the market with open questions,” Skydel said. “Our capacity to answer those questions is really only as strong as FDA and industry’s collaboration,” he added, emphasizing the necessity of post-market enforcement.
Systemic Trust and Public Health Integrity
In an April letter outlining its position, the FDA argued that the debate extends far beyond patients managing a single rare condition. The agency stated that withdrawing the drug “is critical to protect the public health and the integrity of the drug approval process.” Without such enforcement consequences, regulators warn that pharmaceutical companies will retain incentives to act deceptively.
Industry Precedents for Subsequent Market Actors
Walter Kraft, who voted to recommend approving the drug based on the evidence available at the time, voiced broader anxieties regarding knock-on effects across the industry. The clinical trial system “is built on a level of trust,” he said. “And when that trust is put into question for a narrow parochial gain, it puts the whole system at risk for other subsequent actors in the space.”
